slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 18,554
Current window 14,941-14,970
Pages 619
Rows per page 30
Component
14,941-14,970 of 18,554
97
The slide uses highlighted text to emphasize key claims about compound quality and pharmacokinetic challenges.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
100
The slide uses highlighted text to emphasize key quotes from expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
101
The slide uses Q&A format to highlight potential industry knowledge of safety risks that were not publicly disclosed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
102
Uses Q&A format to frame expert opinion as a critique of Bioprojet's claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
106
The slide uses a red box to highlight the 'n=17' discrepancy in the source text.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
107
The slide uses an FDA review document to highlight a safety risk (QTc prolongation) that the company allegedly downplays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
108
The slide uses a direct quote from a study to argue that 'malaise sensation' is a euphemism for 'fainting' (syncope) to downplay cardiotoxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
111
The slide uses a 'villain critique' style to highlight a lack of transparency in clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
113
The slide uses a critical tone to challenge the integrity of the reported clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
115
The slide uses a red underline to emphasize the specific clinical findings in the excerpt.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
116
The slide critiques the authors' interpretation of ECG/QTc data in the HAROSA 2 trial, pointing out potential bias or omission.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
118
The slide uses a 'black box' argument to challenge the validity of the sponsor's pharmacokinetic model.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
119
The slide uses direct quotes from the EMA's CHMP assessment report to highlight regulatory discrepancies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
122
The slide uses a 'before-after' or 'comparison' logic to expose data manipulation in clinical reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
123
The slide uses a red box to highlight a specific data point (40mg dose) in a table to support the argument of inconsistent reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
125
The slide uses a specific data table to support a broader narrative of corporate non-transparency regarding PK data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
128
The slide uses a direct quote from an FDA clinical review to contradict the company's safety claims, supported by a table of clinical data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
129
The slide highlights the safety margin between the recommended dose (40mg) and the doses where QTc prolongation was observed (120-240mg), while noting specific patient populations at higher risk.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
132
The slide highlights a specific discrepancy in an FDA review document (page 32) where the graph title claims 'steady state Cmax' but the underlying data is from a single dose.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
133
The slide uses a red box to highlight the specific column in the table containing the erroneous data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
136
Includes a linear regression equation Y=14.62*X+53.34 and a scatter plot with error bars.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
138
The slide uses direct excerpts from the drug's prescribing information to build a case against its safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
139
The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
141
The slide uses direct citations from peer-reviewed papers to validate the consultant's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
142
The slide uses direct excerpts from regulatory documents to challenge the company's claims regarding drug safety and pharmacokinetics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
145
The slide contrasts the author's critique with a direct excerpt from an FDA Clinical Pharmacology Review.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
146
The slide uses a 'red flag' narrative to challenge the integrity of clinical trial data reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
150
The slide uses a specific calculation (153 ng/mL * 4 * 2 = 1224 ng/mL) to quantify risk.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
152
The slide uses red underlining to highlight specific dangerous medical advice given to patients.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
154
The slide uses a 'villain critique' style to frame the FDA's approval as flawed and the drug's safety as compromised.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit